We use cookies to ensure that we give you the best experience on our website. By continuing to browse the site you are agreeing to our use of cookies. If you would like to know more please click here.


Prof David Klug (Chairman)

David Klug joined the Department of Chemistry at Imperial College London in October 1998, having from October 1995 held a joint position in the Departments of Biochemistry and Chemistry. From October 1990 to September 1995 he was a Royal Society University Research Fellow jointly in Biochemistry and Chemistry. He graduated in Physics at University College London in 1984, and obtained his Ph.D. at The Royal Institution in 1987.

He has been Professor of Chemical Biophysics since 2002 and is co-founder and Chair of the Institute of Chemical Biology (www.chemicalbiology.ac.uk) which co-ordinates teaching and research activities across the life science-physical sciences interface. He also chairs the Single Cell Proteomics Project, a £5 million multidisciplinary collaboration of eight research teams developing and applying novel platform technologies to high throughput and single cell analysis (www.singlecellanalysis.ac.uk) and the Proxomics project (www.proxomics.co.uk) a £4.6 million multidisciplinary research programme between Imperial College London, University of Glasgow and Aston University that has been funded by the Engineering and Physical Sciences Research Council (EPSRC) to focus on the development of new technologies for understanding the causes of ageing and protein-oxidative damage.

David’s own research team is focussed on Single Cell Proteomics for clinical applications and the development of optical analogues of 2DNMR and proteome-on-a-chip technology. More information about his research group can be found at www.ch.ic.ac.uk/klug/index.html

Prof Steve Ley

Steve is the BP (1702) Professor of Chemistry at the University of Cambridge. Prior to joining Cambridge he was at Imperial College where he became Professor in 1983, and Head of Department in 1989. His research interests span natural product synthesis, chemical methodology, flow chemistry and medicinal chemistry. The Ley group have complete 130 total syntheses of natural products including the milbeymycins, avermectins, okadaic acid and tetronasin. Notable achievements in chemical methodology include the invention of the widely used catalytic oxidant TPAP and the development and use pi-allyltricarbonyl complexes for natural product synthesis. Steve has also been a pioneer in flow chemistry and has co-developed many tools in the area as well as publishing many defining papers including the total flow synthesis of oxymaritidine describing a seven step total synthesis in flow using in-line reagents and scavengers. Steve has published over 730 papers to date and his recent awards include the Royal Medal, the Paracelsus Prize, the Heinrich Wieland Prize, the Tetrahedron Prize, the Perkin Prize for Organic Chemistry, the High Throughput Drug Discovery Methodologies Award, the Prous Institute-Overton and Meyer Award for New Technologies in Drug Discovery and the Hans HeroffInhoffen Medal. He was elected to the Royal Society in 1990 and was President of the Royal Society of Chemistry from 2000-2002.

Dr Alan Naylor

Alan Naylor is a medicinal chemist with over 30 years experience in Research and Development within GlaxoSmithKline. He previously held the position of Vice President and Director of Medicinal Chemistry within the GSK Drug Discovery organization and has lead strategic, matrix and line functions involving significant international responsibilities. He has an extensive track record of success, across a wide range of therapeutic areas, having played a major role in the discovery of over 30 development compounds, and is a co-inventor of Serevent, a major advance in the treatment of asthma. Since retiring from GlaxoSmithKline in July 2008 Alan has been an independent consultant providing scientific and strategic advice and analysis to major pharma, biotechnology companies, academic groups, capital investment companies and funding bodies on a variety of issues within the drug discovery and healthcare sector.

Dr Paul England

Paul received his B.Sc. and Ph.D. from the University of Bristol, and after a post-doctoral position with Prof. Edwin Krebs at the University of California, Davis from 1971-73 he returned to the University of Bristol as a Lecturer in Biochemistry. His research speciality was the role of protein phosphorylation in the control of muscle function. In 1985 he joined Smith, Kline & French R&D (subsequently SmithKline Beecham) in the Drug Discovery division. From 1994-1997 he was Vice President Molecular Screening Technologies, in which role he established and managed SB’s entire high throughput screening activities and enzymology worldwide. From 1998-2000 he was Senior Vice President Research at Aurora Biosciences Corp. in San Diego, with responsibility for assay development and screening. He was Chief Executive Officer of ProXara Biotechnology Ltd from 2001-2009, is currently Chairman of Badrilla Ltd and a Director of Iota Pharmaceuticals Ltd, and is a consultant for a number of biotechnology companies and academic groups in the drug discovery area in the UK.